Abstract
Is there a future for antineoplastic triazenes in the clinic? The answer is probably no as they have been under investigation now for nearly two decades without showing satisfactory promise in the treatment of human malignancies. However, 1-aryl-3,3-dialkyltriazenes are certainly very interesting experimental agents. In particular, studies of their metabolism have furnished a marked contribution to our understanding of the link between xenobiochemistry and biological activity. These studies were mostly conducted in the 60s and 70s and they established clearly that aryldialkyltriazenes require metabolism to exert their antineoplastic and carcinogenic activity (for review see ref. 1). More recently the discovery of the remarkable antineoplastic activity in mice of mitozolomide and related imidazotetrazinones, molecules in which the triazene moiety is part of a ring structure, has led to the studies of their mode of action and their metabolism2,3. The role which metabolism plays as a determinant of biological activity is less clear for the imidazotetrazinones than in the case of the aryldimethyltriazenes. In this overview the metabolism of antineoplastic aryldimethyltriazenes and imidazotetrazinones is compared. Such a comparison might eventually contribute to the ultimate assessment of the therapeutic benefit of treatment with these agents, if indeed there is one.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
A. Gescher and M.D. Threadgill, The metabolism of triazene antitumor drugs, Pharmac. Ther. 32: 191 (1987).
C.M.T. Horgan and M.J. Tisdale, Antitumour imidazotetrazines. IV. An investigation into the mechanism of antitmumour activity of a novel and potent antitumour agent, mitozolomide. Biochem. Pharmacol. 33: 2185 (1984).
K.R. Horspool, C.P. Quarterman, J.A. Slack, A. Gescher, M.F.G. Stevens and E. Lunt, Metabolic activation and murine pharmacokinetics of the 8-(N,N-dimethylcarboxamide) analog of the experimental antitumor drug mitozolomide (NSC353451), Cancer Res., 49: 5023 (1989).
R. Preussman and A. von Hodenberg, Mechanism of carcinogensis of 1-aryl-3,3-dialkyltriazenes. Enzymatic dealkylation by rat liver microsomal fraction in vitro, Biochem. Pharmacol. 18: 1 (1969).
P. Farina, A. Gescher, J.A. Hickman, J.K. Horton, M. D’Incaici, D. Ross, M.F.G. Stevens and L.C. Torti, Studies of the mode of action of antitumour triazenes and triazines. IV. The metabolism of 1-(4-acetylphenyl)-3,3-dimethgyltriazene. Biochem. Pharmacol. 31: 1887 (1982).
P. Farina, E. Benfenati, R. Reginato, L. Torti, M. D’Incaici, M.D. Threadgill and A. Gescher, Metabolism of the anticancer agent 1-(4-acetylphenyl)-3,3-dimethyltriazene, Biomed. Mass Spectrom., 10: 485 (1983).
B.L. Pool, Microsomal mediated metabolism of dialkylaryltriazenes. II. Isolation and identification of metabolites of 3,3-dimethyl-1-phenyltriazene, J. Cancer Res. Clin. Oncol. 93: 221 (1979).
A. Gescher, J.A. Hickman, R.J. Simmonds, M.F.G. Stevens and K. Vaughan, Studies of the mode of action of antitumour triazenes and triazines. II. Investigation of the selective toxicity of 1-aryl-3,3,-dimethyltriazenes. Biochem. Pharmacol. 30: 89 (1981).
A. Gescher, J.A. Hickman, R.J. Simmonds, M.F.G. Stevens and K. Vaughan, Alpha-hydroxylated derivatives of antitumour dimethyltriazenes, Tetrahedron Lett. 50: 5041 (1978).
G.F. Kolar and R. Carubelli, Urinary metabolites of 1-(2,4,6-tridhlorophenyl)-3,3,-dimethyltriazene with an intact diazoamino structure, Cancer Lett. 7: 209 (1979).
G.E. Householder and T.L. Loo, Elevated urinary excretion of 4-amino imidazole-5-carboxamide in patients after iv injection of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide, Life Sci. 8: 533 (1969).
J.L. Skibba, G. Ramirez, D.D. Beal and G.T. Bryan, Metabolism of 4(5)-(3,3-dimethyl-1-triazeno)-imidazole-5(4)-carboxamide to 4(5)-amino-imidazole-5(4)carboxamide in man, Biochem. Pharmacol. 19: 2043 (1970).
N.S. Mizuno and E.W. Humphrey, Metabolism of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC 45388) in human and tumor tissue, Cancer Chemother. Rep. 56: 465 (1972).
D.L. Hill, Microsomal metabolism of triazenylimidazoles, Cancer Res. 35: 3106 (1975).
G.F. Kolar, M. Maurer and M. Wildschütte, 5-(3-Hydroxymethyl-3-methyltriazeno)imidazo-4-carboxamide, a metabolite of dacarbazine (DIC, DTIC, NSC 45388), Cancer Lett. 10: 241 (1980).
M.F.G. Stevens, J.A. Hickman, R. Stone, N.W. Gibson, E. Lunt, C.G. Newton and G.U. Baig, Antitumor imidazotetrazines. I. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5„l-d]-l,2,3,5-tetrazine-4(3H)-one, a novel broad spectrum antitumor agent, J. Med. Chem. 27: 196 (1984).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gescher, A., Tsang, L.L.H., Slack, J.A. (1990). The Metabolism of Antineoplastic Triazenes. In: Giraldi, T., Connors, T.A., Cartei, G. (eds) Triazenes. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3832-5_7
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3832-5_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6710-9
Online ISBN: 978-1-4615-3832-5
eBook Packages: Springer Book Archive